Canada Blood Group Typing Market Analysis

Canada Blood Group Typing Market Executive Summary

The Canada Blood Group Typing Market is at around $275.20 Mn in 2023 and is projected to reach $526.13 Mn in 2030, exhibiting a CAGR of 9.70% during the forecast period.

Blood typing is a method to tell what type of blood the individual has. Blood typing is done so they can safely donate or receive a blood transfusion. Blood group determination helps understand a person’s blood group and determine the presence of Rh factor in RBCs. ABO and Rh blood group typing procedures are used to determine an individual’s blood type, which is essential for safe blood transfusions. The presence or lack of specific proteins on RBCs known as antigens shape a person’s blood type, which is inherited from their parents. Four main blood types are distinguished using the ABO blood typing system: Type A, Type B, Type AB, and Type O.

Blood typing is important for several reasons like, safe blood transfusions and matching donor and recipient blood types prevent potentially life-threatening transfusion reactions. Pregnant women must know their blood type, especially the Rh factor. This helps prevent complications like hemolytic disease in the newborn. Blood typing can provide information for genetic studies and inheritance patterns. It also plays a key factor in organ transplant matching to reduce the risk of organ rejection.

The increase in donations over the years signifies that the number of blood group typing procedures has also increased. Furthermore, the increasing prevalence of diseases associated with blood, such as sickle cell anemia, thalassemia, lymphoma, leukemia, and haemophilia, is also supporting the growth of blood group typing. Approximately 5,000 Canadians live with sickle cell disease. The market therefore is driven by significant factors like the increase in prevalence of chronic diseases, public initiatives, and rising number of surgical procedures. However, cost constraints, geographical challenges, and regulatory challenges restrict the growth of the market.

The prominent companies for blood group typing include Grifols Canada and Bio-Rad Laboratories. Beckman Coulter, Quotient Limited, and Immucor, Inc. are also significant contributors to Canada Blood Group Typing Market.

Market Dynamics

Market Growth Drivers

Increasing Prevalence of Chronic Diseases: The rise in chronic diseases, such as cancer and cardiovascular conditions, necessitates more frequent blood typing for effective treatment and management. More than 1.5 million Canadians (nearly 4% of the population) are living with cancer. This is contributing to the growing demand for blood typing services in clinical settings

Public Initiatives: Increased public awareness regarding the importance of blood donation and typing by Canadian Blood Services is leading to higher participation in blood donation drives. This is crucial for maintaining adequate blood supplies and ensuring that blood typing services can meet demand

Rising Number of Surgical Procedures: As the frequency of surgical procedures increases, so does the need for blood typing to ensure compatibility for transfusions. The growing number of elective and emergency surgeries directly drives the demand for blood typing services.

Market Restraints

Cost Constraint: Adopting advanced blood typing methods like polymerase chain reaction (PCR) and next-generation sequencing (NGS) can be expensive, especially for smaller healthcare facilities and blood banks. The significant expenses involved in acquiring and maintaining sophisticated equipment restrict access to these technologies, particularly in settings with limited resources.

Geographical Challenge: Canada's vast size makes it challenging to collect, transport, and deliver blood promptly, especially in remote areas. Blood collection centers are often concentrated in urban areas, leaving remote communities with limited access to blood services. Timely delivery of blood is essential, but perishable blood products can expire during transport, especially in remote areas.

Regulatory Challenge: The blood typing market is subject to stringent regulatory standards that govern blood transfusions and testing procedures. Compliance with these regulations requires substantial investments in training, quality control, and technology, which can be challenging for smaller organizations to sustain. The complexity of maintaining compliance may deter some facilities from adopting advanced blood typing methods

Regulatory Landscape and Reimbursement Scenario

Health Canada is the primary regulatory body overseeing the safety of the blood supply in Canada. It establishes regulations that blood operators must follow to ensure the safety and quality of blood and blood components for transfusion and further manufacturing. Canadian Standards Association (CSA) Blood Standard is referenced in the Blood Regulations and outlines safety, efficacy, and quality requirements for blood collection, processing, and transfusion. Compliance with this standard is mandatory for blood operators.

Blood products, including those related to blood typing, are typically funded by provincial health ministries. Hospitals do not directly purchase blood products; instead, they receive them at no charge from CBS or Héma-Québec.

Competitive Landscape

Key Players

Here are some of the major key players in the Canada Blood Group Typing Market:

• Grifols Canada
• Bio-Rad Laboratories
• Ortho Clinical Diagnostics
• Beckman Coulter
• Roche Diagnostics
• Quotient Limited
• Immucor, Inc.
• Abbott Laboratories
• Diasorin
• BAG Diagnostics GmbH